Vitamin E
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Vitamin E
- Pharmacist Assessment Report
- Vitamin E: From Cholestasis-Related Vitamin E Deficiency to Inborn Disorder of Bilirubin Metabolism
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Vitamin E: From Cholestasis-Related Vitamin E Deficiency to Inborn Disorder of Bilirubin Metabolism
One-Sentence Summary
Vitamin E was originally used to treat vitamin E deficiency in cholestatic liver disorders, including benign recurrent and familial intrahepatic cholestasis and familial isolated vitamin E deficiency. The TxGNN model predicts it may be effective for inborn disorder of bilirubin metabolism. However, there are no registered clinical trials and only 1 publication that bears on this prediction, so it rests almost entirely on the model’s prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Cholestasis, benign recurrent intrahepatic cholestasis, familial intrahepatic cholestasis, familial isolated deficiency of vitamin E (the Canadian licence records contain no approved-indication text) |
| Predicted New Indication | Inborn disorder of bilirubin metabolism |
| TxGNN Prediction Score | 0.9999 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 5 of 7; dormant: 2) |
| Number of DINs | 7 (marketed: 5) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, vitamin E is a fat-soluble antioxidant that is already used as supportive therapy for fat-soluble vitamin malabsorption in cholestatic disorders. Mechanistically, it may be applicable to inherited disorders of bilirubin handling that overlap with cholestasis.
The link is indirect. The only retrieved paper (PMID 7915305) describes a bile acid synthesis defect (3-beta-hydroxy-C27-steroid dehydrogenase deficiency) that causes progressive intrahepatic cholestasis. That connects to the cholestasis-related vitamin E deficiency seen in the original indications, not to any effect of vitamin E on bilirubin metabolism itself.
The very high TxGNN score is a computational prediction and is not backed by clinical data. Other highly ranked predictions, such as bilirubin metabolism disease, drug-induced liver injury and hyperbiliverdinemia, have similarly weak or indirect support.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 7915305 | 1994 | Case series | The Journal of Pediatrics | Screening of 30 children with progressive intrahepatic cholestasis (Byler disease) identified 3-beta-hydroxy-C27-steroid dehydrogenase/isomerase deficiency, a bile acid synthesis defect, as a new cause. It does not test vitamin E. |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 00586315 | MULTI 1000 | Not stated | Not stated |
| 02100606 | MULTI 12 | Not stated | Not stated |
| 02242529 | MULTI-12/K1 PEDIATRIC | Not stated | Not stated |
| 02552639 | PREGVIT FOLIC 5 | Not stated | Not stated |
| 02535718 | PREGNANCY MULTIVITAMIN | Not stated | Not stated |
All 7 licences are valid entries; the table lists the first 5. The remaining two are PREGVIT (02552620) and PREGNANCY MULTIVITAMIN FOLIC 5 (02537478).
Safety Considerations
- Drug Interactions: 100 interactions were identified, and 20 are detailed here.
- Moderate: acetylsalicylic acid, iron, sevelamer, iron sucrose, and several antithrombotic or anticoagulant agents (abciximab, antithrombin III human, apixaban, dipyridamole, betrixaban, bivalirudin, cangrelor, caplacizumab). These warrant attention for bleeding risk.
- Minor: corticosteroids (hydrocortisone, triamcinolone, dexamethasone, betamethasone, budesonide, prednisone, prednisolone) and orlistat.
Please refer to the package insert for other safety information, including warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no registered trials and a single, indirect publication. The evidence level is L5, so there is no clinical basis to support vitamin E for inherited bilirubin metabolism disorders. The vitamin E safety profile and its widespread Canadian availability do not by themselves justify moving forward.
To proceed, the following is needed:
- Mechanism of action data linking vitamin E to bilirubin metabolism
- Health Canada package insert warnings and contraindications, needed for safety screening
- Targeted literature review or preclinical and clinical studies in inherited bilirubin disorders (for example Crigler-Najjar or Gilbert syndrome)
- Review of the other predicted indications (such as drug-induced liver injury, which has only preclinical and indirect support) to see whether any offers a stronger starting point
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.